A randomized phase 2 study of abemaciclib versus docetaxel in patients with stage IV squamous non-small cell lung cancer (sqNSCLC) previously treated with platinum-based chemotherapy.

Giorgio V. Scagliotti(Ospedale San Luigi Gonzaga), Ramaswamy Govindan(Washington University in St. Louis), Sameera R. Wijayawardana(Eli Lilly (United States)), Shawn T. Estrem, Helge Bischoff(Heidelberg University), David Vicente(Hospital Universitario Virgen Macarena), Karla Hurt(Eli Lilly (United States)), Maciej Bryl, Andrea Fülöp(Országos Korányi Tbc és Pulmonológiai Intézet), Yi Lu(Shandong Provincial Hospital), Tudor–Eliade Ciuleanu(Institute of Oncology Prof. Dr. Ion Chiricuta), Alan Y. Chiang(Eli Lilly (United States)), Igor Bondarenko(Dnipro State Medical University)
Journal of Clinical Oncology
May 20, 2018
10.1200/jco.2018.36.15_suppl.9059
Cited by 10

Related Papers

International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2008|3.2k
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
|The Lancet|2005|2.1k